Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert


Search Title by author or title

Severe ocular pemphigoid treated with a combination therapy of intravenous immunoglobulin and rituximab

Poster Details

First Author: A. Calle SPAIN

Co Author(s):    B. Sarmiento Torres   J. Torres Pena   C. Navarro Perea   L. Hernandez Pereira   A. Ortueta Olartecoechea   A. De Pablo Cabrera     

Abstract Details


To report a severe ocular pemphigoid case treated with a combination therapy of intravenous immunoglobulin (IVIg) and rituximab


12 de Octubre Universitary Hospital, Ophthalmology Deparment, Complutense University, Madrid, Spain


A 80 years-old woman with diagnosis of severe ocular pemphigoid with no response to high-dose corticosteroids, cyclophosphamide, cyclosporin, azathioprine, dapsone, and mycophenolate mofetil. The diagnosis was based on histopathology and confirmed by direct immunofluorescence. In this case we decided to use combination therapy with intravenous immunoglobulin 660mg/kg (Octagamocta®) and rituximab 375 mg/m2 (Mabthera®) 3 doses each, monthly, during 3 months.


After 3 months of treatment with IVIg and rituximab, there was no progression in conjunctival cicatrization meaning an stabilization of the severe ocular compromise.


In cases of severe ocular pemphigoid with not response to conventional immunosuppressive therapy, the combination therapy with IVIg and rituximab could be used to stop the progression of the severe ocular compromise

Financial Disclosure:


Back to Poster listing